Posaconazole should be considered!

“Posaconazole should be considered an alternative for prophylaxis in patients with severe graft-versus-host disease,” Dr.
Ullmann and his associates conclude.

A
prospective legal proceeding, led by Dr.
Oliver A.
Cornely at the Establishment of Perfume in Germany, compared safety
treatments among neutropenic patients with acute myelogenous leukemia
or the myelodysplastic composite.

The
written document took function between 2002 and 2005 at 89 centers.
Leash hundred four patients were randomized to posaconazole; 240
patients were randomized to fluconazole; and 58 to itraconazole.
Each drug was administered as an oral intermission: posaconazole (200
mg t.i.d.), fluconazole (400 mg q.d.) or itraconazole (Sporanox,
Janssen, 200 mg b.i.d.).

During
the 100-day menstruation after randomization, invasive fungal
infections occurred in 5% in the posaconazole abstraction versus 11% in
the fluconazole/itraconazole building block (p = 0.003).
Boilersuit rate during the same interval was 14% and 21%, respectively
(p = 0.04), while corresponding impermanence rates due to fungal
unhealthiness were 2% and 5% (p = 0.01).

Compared
with Dr.
Ullmann’s abstraction, Dr.
Cornely’s team observed more frequent serious adverse events possibly
or probably related to discussion in the posaconazole set (6%) versus
2% in the fluconazole/itraconazole radical (p = 0.01).
This is a part of article Posaconazole should be considered! Taken from "Buy Diflucan Fluconazole" Information Blog